Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.

ABSTRACT:

SUBMITTER: Faivre-Finn C 

PROVIDER: S-EPMC5555437 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature